Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.

Impaired blood circulation in the lower limbs is a common health problem among the elderly and one of the most prominent ...

Impaired blood circulation in the lower limbs is a common health problem among the elderly and one of the most prominent ...

Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

The Phase III trial AV001 aims to evaluate QUTENZA® in post- surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after ...

As part of its ongoing RAK diabetes Challenge community initiative, RAK Hospital held an insightful Diabeat Webinar on the LINK between diabetes and kidney disease, shedding light on the prevention ...

As part of its ongoing RAK Diabetes Challenge community initiative, RAK Hospital held an insightful Diabeat Webinar on the ...

In August, Trevena underwent a reverse stock split, a move often enacted when a company’s share price dips too low. The split wasn’t enough to stave off delisting, with Nasdaq removing Trevena’s stock ...

The Phase III trial AV001 aims to evaluate QUTENZA in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...

TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P 1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic ...

Anti-neurofascin 186 antibodies, a dedicated test for autoimmune neuropathy (nodpathies/paranodopathies) was positive ...